DANIELLE DOEBEREINER-BROWN: Open Payments
NPI 1225564917 · CARROLLTON, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$383 in 14 payments from 8 companies in 2025. Trend: 2023 $236 · 2024 $364 · 2025 $383
Food & beverage: $383
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 1 | $121 |
| Novo Nordisk Inc | 4 | $72 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $63 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $48 |
| GlaxoSmithKline, LLC. | 1 | $24 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $23 |
| Lilly USA, LLC | 1 | $19 |
| ABBVIE INC. | 1 | $15 |
Products named: TEZSPIRE, CAPLYTA, ENTYVIO, Wegovy, SHINGRIX, XIFAXAN, JARDIANCE, Ozempic.
Industry payments across GA — which companies pay providers there.
